Future antidepressants: What is in the pipeline and what is missing?

CNS Drugs

Volumn 18, Issue 11, 2004, Pages 705-732

  Bosker, Fokko J ^a,b   Westerink, Ben H C ^b   Cremers, Thomas I F H ^a,b   Gerrits, Marjolein ^a,b   Van Der Hart, Marieke G C ^a,b   Kuipers, Sjoukje D ^a,b   Van Der Pompe, Gieta ^a,b   Ter Horst, Gert J ^a,b   Den Boer, Johan A ^a,b   Korf, Jakob ^a,b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

4 (2 FLUOROPHENYL) 6 METHYL 2 (1 PIPERAZINYL)THIENO[2,3 D]PYRIMIDINE; 4 METHYL 2 [4 [4 (2 PYRIMIDINYL)PIPERAZINO]BUTYL] 2H,4H 1,2,4 TRIAZINE 3,5 DIONE; 7 (4 METHYL 1 PIPERAZINYL) 2(3H) BENZOXAZOLONE; [[7 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO] 5,6,7,8 TETRAHYDRO 2 NAPHTHYL]OXY]ACETIC ACID ETHYL ESTER; ADATANSERIN; ANTIDEPRESSANT AGENT; ANTIINFLAMMATORY AGENT; APREPITANT; DDP 225; DOV 216303; DU 125530; DULOXETINE; ELZASONAN; EPTAPIRONE; FLEROBUTEROL; FLUOXETINE; GEPIRONE; NKP 608; OLANZAPINE; ORG 12962; OSEMOZOTAN; R 673; RISPERIDONE; SELEGILINE; SEROTONIN 1A AGONIST; SEROTONIN 1A ANTAGONIST; SEROTONIN 2C ANTAGONIST; SL 251131; SULPIRIDE; TAK 637; UNCLASSIFIED DRUG; VESTIPITANT; VILAZODONE; WAY SEB 324;

CLINICAL TRIAL; DEPRESSION; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG TARGETING; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MAJOR DEPRESSION; MONOAMINERGIC SYSTEM; NEUROBIOLOGY; NEUROIMMUNOLOGY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RECEPTOR BLOCKING; REVIEW; SEX DIFFERENCE; SIDE EFFECT; STRESS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIDEPRESSIVE AGENTS; BIOGENIC MONOAMINES; CYTOKINES; DEPRESSION; FORECASTING; HORMONES; HUMANS; NEUROPEPTIDES; RECEPTORS, CELL SURFACE;

EID: 4644356824     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200418110-00002     Document Type: Review

References (264)

1. Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of the supporting evidence. Am J Psychiatry 1965; 122: 509-21
2. Steffens DC, Krishnan KR, Helms MJ. Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: a meta-analysis. Depress Anxiety 1997; 6: 10-8
3. Kirsch I, Moore TJ, Scoboria A, et al. The emperor's new drugs: an analysis of antidepressant medication data submitted to the US Food and Drug Administration. Prevention & Treatment I 2002, Article 23 [online]. Available from URL: http://www.journals.apa.org/prevention [Accessed 2003 Jul 15]
4. Syvalahti EK. Biological aspects of depression. Acta Psychiatr Scand 1994; 377: 11-5
5. Stockmeier CA. Neurobiology of serotonin in depression and suicide. Ann N Y Acad Sci 1997; 836: 220-32
6. Drevets WC, Videen TO, Price JL, et al. A functional anatomical study of unipolar depression. J Neurosci 1992; 12: 3628-41
7. Drevets WC, Price JL, Bardgett ME, et al. Glucose metabolism in the amygdala in depression: relationship to diagnostic subtype and plasma cortisol levels. Pharmacol Biochem Behav 2002; 71: 431-47
8. Holsboer F. Antidepressant drug discovery in the postgenomic era. World J Biol Psychiatry 2001; 2: 165-77
9. Yamada M, Higuchi T. Functional genomics and depression research: beyond the monoamine hypothesis. Eur Neuropsychopharmacol 2002; 12: 235-44
10. Marsden CA, Stanford SC. CNS drugs III: psychotherapeutics. Expert Opin Investig Drugs 2000; 9: 1923-9
11. Davidsson P, Brinkmalm A, Karlsson G, et al. Clinical mass spectrometry in neuroscience: proteomics and peptidomics. Cell Mol Biol 2003; 49: 681-8
12. Delgado PL. Depression: the case for a monoamine deficiency. J Clin Psychiatry 2000; 61 Suppl. 6: 7-11
13. Hirschfeld RM. History and evolution of the monoamine hypothesis of depression. J Clin Psychiatry 2000; 61 Suppl. 6: 4-6
14. Shelton RC. Cellular mechanisms in the vulnerability to depression and response to antidepressants. Psychiatr Clin North Am 2000; 23: 713-29
15. Kempermann G. Regulation of adult hippocampal neurogenesis - implications for novel theories of major depression. Bipolar Disord 2002; 4: 17-33
16. Coyle JT, Duman RS. Finding the intracellular signaling pathways affected by mood disorder treatments. Neuron 2003; 38: 157-60
17. Manji HK, Quiroz JA, Sporn J, et al. Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry 2003; 53: 707-42
18. Gold PW, Chrousos GP. Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs low CRH/NE states. Mol Psychiatry 2002; 7: 254-75
19. Zarate Jr CA, Du J, Quiroz J, et al. Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: role of the glutamatergic system. Ann N Y Acad Sci 2003; 1003: 273-91
20. Seabrook GR, Easter A, Dawson GR, et al. Modulation of long-term potentiation of CA1 region of mouse hippocampal brain slices by GABAA receptor benzodiazepine site ligands. Neuropharmacology 1997; 36: 823-30
21. Kessler RC, McGonagle KA, Swartz M, et al. Sex and depression in the National Comorbidity Survey: I. lifetime prevalence, chronicity and recurrence. J Affect Disord 1993; 29: 85-96
22. Weissman MM, Olfson M. Depression in women: implications for health care research. Science 1995; 269: 799-801
23. Song F, Freemantle N, Sheldon TA, et al. Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. BMJ 1993; 306: 683-7
24. Montgomery SA, Henry J, McDonald G, et al. Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates. Int Clin Psychopharmacol 1994; 9: 47-53
25. Anderson IM, Tomenson BM. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis. BMJ 1995; 310: 1433-8
26. Anderson IM. SRIs versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depress Anxiety 1998; 7: 11-7
27. Meana JJ, Barturen F, Garcia-Sevilla JA. Alpha 2-adrenoceptors in the brain of suicide victims: increased receptor density associated with major depression. Biol Psychiatry 1992; 1: 471-90
28. Bech P, Cialdella P. Citalopram in depression: meta-analysis of intended and unintended effects. Int Clin Psychopharmacol 1992; 6 Suppl. 5: 45-54
29. Bech P. Clinical effects of selective serotonin reuptake inhibitors. In: Dahl SG, Gram LF, editors. Clinical pharmacology in psychiatry. Berlin: Springer, 1989: 81-93
30. Mendlewicz J. Efficacy of fluvoxamine in severe depression. Drugs 1992; 43 Suppl. 2: 32-7
31. Tignol J, Stoker MJ, Dunbar GC. Paroxetine in the treatment of melancholia and severe depression. Int Clin Psychopharmacol 1992; 7: 91-4
32. Doogan DP, Caillard V. Sertraline in the prevention of depression. Br J Psychiatry 1992; 160: 217-22
33. Franchini L, Gasperinin M, Perez J, et al. A double-blind study of long-term treatment with sertraline or fluvoxamine for prevention of highly recurrent unipolar depression. J Clin Psychiatry 1997; 58: 104-7
34. Keller MB, Gelenberg AJ, Hirschfeld RM, et al. The treatment of chronic depression, part 2: a double-blind, randomized trial of sertraline and imipramine. J Clin Psychiatry 1998; 59: 598-607
35. Keller MB, Kocsis JH, Thase ME, et al. Maintenance phase efficacy of sertraline for chronic depression: a randomized controlled study. JAMA 1998; 280: 1665-72
36. Montgomery SA, Dunbar GC. Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. Int Clin Psychopharmacology 1993; 8: 189-95
37. Montgomery SA, Rasmussen JG, Tanghoj P. A 24-week study of 20mg citalopram, 40mg citalopram and placebo in the prevention of relapse of major depression. Int Clin Psychopharmacol 1993; 8: 181-8
38. Montgomery SA, Kasper S. Comparison of compliance between serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. Int Clin Psychopharmacol 1995; 9 Suppl. 4: 33-40
39. Robert P, Montgomery SA. Citalopram in doses of 20-60mg is effective in depression relapse prevention: a placebo-controlled 6 month study. Int Clin Psychopharmacol 1995; 10 Suppl. 1: 29-35
40. Rush AJ, Koran LM, Keller MB, et al. The treatment of chronic depression, part 1: study design and rationale for evaluating the comparative efficacy of sertraline and imipramine as acute, crossover, continuation, and maintenance phase therapies. J Clin Psychiatry 1998; 59: 589-97
41. den Boer JA, Westenberg HGM. Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder; a double-blind comparative study with fluvoxamine and maprotiline. Int Clin Psychopharmacol 1988; 3: 59-74
42. Turner SM, Jacob RG, Beidel DC. Fluoxetine in the treatment of obsessive compulsive disorder. J Clin Psychopharmacol 1985; 5: 207-12
43. Perse TL, Greist JH, Jefferson JW. Fluvoxamine treatment of obsessive-compulsive disorder. Am J Psychiatry 1987; 144: 1543-8
44. Van Vliet IM, den Boer JA, Westenberg HG. Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine. Psychopharmacology 1994; 115: 128-34
45. Rickels K, London J, Fox I. Adinazolam, diazepam, imipramine, and placebo in major depressive disorder: a controlled study. Pharmacopsychiatry 1991; 24: 127-31
46. Smith D, Dempster C, Glanville J, et al. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry 2002; 180: 396-404
47. Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Dis 2000; 58: 19-36
48. Ishigooka J, Murasaki M. First open study with new antidepressant 248686 (Duloxetine for depression in Japan [abstract]. Eur Neuropsychopharmacol 1996; 6 Suppl. 3: 50
49. Berk M, Du Plessis AD, Birkett M, et al. An open-label study of fluoxetine hydrochloride, a mixed serotonin and norepineprhine reuptake inhibitor, in patients with DSM III R major depressive disorder. Int Clin Psychopharmacol 1997; 12: 137-40
50. Nemeroff CB, Schatzberg AF, Goldstein DJ, et al. Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull 2002; 36: 106-32
51. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res 2002; 36: 383-90
52. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002; 63: 308-15
53. Goldstein DJ, Mallinckrodt C, Lu Y, et al. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry 2002; 63: 225-31
54. Raskin J, Goldstein DJ, Mallinckrodt CH, et al. Duloxetine in the long-term treatment of major depressive disorder. J Clin Psychiatry 2003; 64: 1237-44
55. Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol 2004; 24: 389-99
56. Dov Pharmaceuticals [online]. Available from URL: http://www.dovpharm.com [Accessed 2002 Sep 3]
57. Murck H, Held K, Frieboes RM, et al. Fast adaptive changes of the sleep regulatory system after a single dose of the putative antidepressant substance EMD 68843. Int J Neuropsychopharmacol 2000; 3 Suppl. 1: 197
58. Eguchi J, Inomata Y, Yuasa T. Pharmacological profile of the novel antidepressant 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno-[2,3-d] pyrimidine monohydrate hydrochloride. Arzneimittel Forschung 1997; 47: 1337-47
59. Rausch JL, Ruegg R, Moeller FG. Gepirone as a 5-HT1A agonist in the treatment of major depression. Psychopharmacol Bull 1990; 26: 169-71
60. Jenkins SW, Robinson DS, Fabre LF, et al. Gepirone in the treatment of major depression. J Clin Psychopharmacol 1990; 10 Suppl. 3: 77S-85S
61. McGrath PJ, Stewart JW, Quitkin FM, et al. Gepirone treatment of atypical depression: preliminary evidence of serotonergic involvement. J Clin Psychopharmacol 1994; 14: 347-52
62. Wilcox CS, Ferguson JM, Dale JL, et al. A double-blind trial of low- and high dose ranges of gepirone-ER compared with placebo in the treatment of depressed outpatients. Psychopharmacol Bull 1996; 32: 335-42
63. Gibertini M, Davidson J. Effect of gepirone-ER on sexual function in patients with major depression. Poster presented at CINP 2002. Int J Neuropsychopharmacol 2002; 5 Suppl. 1: P3E 020 Montreal
64. Gibertini M, Heiser JF, Shrivastava RK, et al. Gepirone Extended Release (ER): new evidence for efficacy in the treatment of major depressive disorder (MDD). Poster presented at CINP 2002. CINP 2002, P3E 019 Montreal
65. Gibertini M, Quitkin FM. Patient response in depression with overeating and oversleeping to gepirone-ER. Poster presented at CINP 2002. Int J Neuropsychopharmacol 2002; 5 Suppl. 1: P3E 009 Montreal
66. Koek W, Patoiseau JF, Assie MB, et al. F 11440, a potent, selective, high efficacy 5-HT1A receptor agonist with marked anxiolytic and antidepressant potential. J Pharmacol Exp Ther 1998; 287: 266-83
67. Mos J, van Hest A, van Drimmelen M, et al. The putative 5-HT1A receptor antagonist DU 125530 blocks the discriminative stimulus of the 5-HT1A receptor agonist flesinoxan in pigeons. Eur J Pharmacol 1997; 325: 145-53
68. Olivier B, Molewijk HE, van der Heyden JAM, et al. Ultrasonic vocalizations in rat pups: effects of serotonergic ligands. Neurosci Biobehav Rev 1998; 23: 215-27
69. Rabiner EA, Wilkins MR, Turkheimer F, et al. 5-Hydroxytryptamine1A receptor occupancy by novel full antagonist 2-[-[-(7-chloro-2,3-dihydro-1,4- benzdioxyn-5-yl)-1-piperazinyl]-utyl]1,2-benzisothiazol-3-(2H)-one-1,1-dioxide: A [1C]cad91]O-methyl-3H]N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2- pyridinyl)cyclohexanecarboxamide trihydrochloride (WAY-100635) positron emission tomography study in humans. J Pharmacol Exp Ther 2002; 301: 1144-50
70. Zini R, Morin D, Martin P, et al. Interactions of flerobuterol, an antidepressant drug candidate, with beta adrenoceptors in the rat brain. J Pharmacol Exp Ther 1991; 259: 414-22
71. Duteil J, Rambert FA, Pointeau AM, et al. Flerobuterol: a potential antidepressant drug related to beta-adrenergic agonists: experimental profile in mice. Fundam Clin Pharmacol 1991; 5: 695-708
72. Simiand J, Keane PE, Guitard J, et al. Antidepressant profile in rodents of SR 58611A, a new selective agonist for atypical beta-adrenoceptors. Eur J Pharmacol 1992; 219: 193-201
73. Barrett JE, Zhang L. Anticonflict and discriminative stimulus effects of the 5-HT1A compounds WY-47,846 and WY-48,723 and the mixed 5-HT1A agonist/5-HT2 antagonist WY-50,324 in pigeons. Drug Dev Res 1991; 24: 179-88
74. Shropshire AT, Piesla MJ, Moyer JA, et al. Diazepam produces partial generalization to the discriminative stimulus effects of WAY-SEB-324, a 5-HT1A partial agonist/5-HT2 antagonist anxiolytic/antidepressant. FASEB J 1993; 7: A256, Part I
75. Abou-Gharbia MA, Childers Jr WE, Fletcher H, et al. Synthesis and SAR of adatanserin: novel adamantyl aryl- and heteroarylpiperazines with dual serotonin 5-HT(1A) and 5-HT(2) activity as potential anxiolytic and antidepressant agents. J Med Chem 1999; 42: 5077-94
76. Matsuda T, Somboonthum P, Suzuki M, et al. Antidepressant-like effect by postsynaptic 5-HT1A receptor activation in mice. Eur J Pharmacol 1995; 280: 235-8
77. Abe M, Tabata R, Saito K-I, et al. Novel benzodioxan derivative, 5-(3-((2S)-1,4-benzodioxan-2-ylmethyl)amino)propoxy)-1,3-benzodioxole HCl (MKC-242), with anxiolytic-like and antidepressant-like effects in animal models. J Pharmacol Exp Ther 1996; 278: 898-905
78. Feenstra R, Ronken E, Koopman T, et al. SLV 308. Drugs of the Future 2001; 26: 128-32
79. Sunderland T, Cohen RM, Molchan S, et al. High-dose selegiline in treatment-resistant older depressive patients. Arch Gen Psychiatry 1994; 51: 607-15
80. Robinson DS, Moonsammy G, Sharoky M. Efficacy and safety of two phase III studies with selegiline transdermal system in the treatment of major depression. CINP 2002, P3E 016 Montreal
81. Bodkin JA, Amsterdam JD. Transdermal selegine in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients. Am J Psychiatry 2002; 159: 1869-75
82. Amsterdam JD. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. J Clin Psychiatry 2003; 64: 208-14
83. Benedictis E. 20mg transdermal selegiline daily may be effective and well tolerated in adults with major depression [letter]. Evid Based Ment Health 2003; 6: 44
84. Mylan Laboratories Inc. Mylan Laboratories and Watson Pharmaceuticals announce receipt of "approvable" letter for Emsam [online]. Available from URL: http://www.drugs.com/nda_emsam_040202.html [Accessed 2004 July 26]
85. Price LH. Lithium augmentation and tricyclic-resistant depression. In: Extein I, editor. Treatment of tricyclic-resistant depression. Washington, DC: American Psychiatric Press, 1998: 51-9
86. Joffe RT, Levitt AJ, Sokolov ST. Augmentation strategies: focus on anxiolytics. J Clin Psychiatry 1996; 57 Suppl. 7: 25-33
87. Blier P, de Montigny C, Chaput Y. Modifications of the serotonin system by antidepressant treatments: implications for the therapeutic response in major depression. J Clin Psychopharmacol 1987; 7 Suppl. 6: 24S-35S
88. Artigas F. 5-HT and antidepressants: new views from microdialysis studies [letter]. Trends Pharmacol Sci 1993; 14: 262
89. 1A agonist activity of pindolol: reversal of the inhibitory effects on cell firing in the dorsal raphe nucleus but not in the hippocampus by WAY-100, 635. Ann N Y Acad Sci 1998; 861: 274-5
90. 1A agonist potential of pindolol: electrophysiologic studies in the dorsal raphe nucleus and hippocampus. Biol Psychiatry 2000; 47: 1050-5
91. Cremers TI, Wiersma LJ, Bosker FJ, et al. Is the beneficial antidepressant effect of coadministration of pindolol really due to somatodendrittc autoreceptor antagonism? Biol Psychiatry 2001; 50: 13-21
92. Kreiss D, Lucki E. Chronic administration of the 5-HT1A receptor agonist 8-OH-DPAT differentially desensitizes 5-HT1A autoreceptors of the dorsal and median raphe nuclei. Synapse 1997; 25: 107-16
93. Bouwer C, Stein DJ. Buspirone is an effective augmenting agent of serotonin selective re-uptake inhibitors in severe treatment refractory depression. S Afr Med J 1997; 87 Suppl. 4: 534-7
94. Jacobsen FM. Possible augmentation of antidepressant response by buspirone. J Clin Psychiatry 1991; 52: 217-20
95. Joffe RT, Schuller DR. An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. J Clin Psychiatry 1993; 54: 269-71
96. Harvey KV, Balon R. Augmentation with buspirone: a review. Ann Clin Psychiatry 1995; 7: 143-7
97. Landen M, Bjorling G, Agren H, et al. A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression. J Clin Psychiatry 1998; 59: 664-8
98. Cremers TI, Giorgetti M, Bosker FJ, et al. Inactivation of 5-HT(2C) receptors potentiates consequences of serotonin reuptake blockade [Epub ahead of print]. Neuropsychopharmacology 2004
99. Cremers TI, de Boer P, Liao Y, et al. Augmentation with a 5-HT(1A), but not a 5-HT(1B) receptor antagonist critically depends on the dose of citalopram. Eur J Pharmacol 2000; 397 (1): 63-74
100. Redrobe JP, Bourin M. Partial role of 5-HT2 and 5-HT3 receptors in the activity of antidepressants in the mouse forced swimming test. Eur J Pharmacol 1997; 325: 129-35
101. Martin JR, Ballard TM, Higgins GA. Influence of the 5-HT2C receptor antagonist, SB-242084, in tests of anxiety. Pharmacol Biochem Biohav 2002; 71 (4): 615-25
102. Sharpley AL, Elliott JM, Attenburrow MJ, et al. Slow wave sleep in humans: role of 5-HT2A and 5-HT2C receptors. Neuropharmacol 1994; 33: 467-71
103. Armitage R, Rush AJ, Trivedi M, et al. The effects of nefazodone on sleep architecture in depression. Neuropsychopharmacology 1994; 10: 123-7
104. Rush AJ, Armitage R, Gillin JC, et al. Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder. Biol Psychiatry 1998; 44: 3-14
105. Hicks JA, Argyropoulos SV, Rich AS, et al. Randomised controlled study of sleep after nefazodone or paroxetine treatment in patients with depression. Br J Psychiatry 2002; 180: 528-35
106. Michelson D, Kociban K, Tamura R, et al. Mirtazapine, yohimbine or olanzapine augmentation therapy for serotonin reuptake-associated female sexual dysfunction: a randomized, placebo controlled trial. J Psychiatr Res 2002; 36: 147-52
107. Hoes MJ, Zeijpveld JH. Mirtazapine as treatment for serotonin syndrome [letter]. Pharmacopsychiatry 1996; 29: 81
108. Graudins A, Stearman A, Chan B. Treatment of the serotonin syndrome with syproheptadine. J Emerg Med 1998; 16: 615-9
109. Klaassen T, Ho-Pian KL, Westenberg HGM, et al. Serotonin syndrome after challenge with the 5-HT agonist meta-chlorophenylpiperazine. Psychiatry Res 1998; 79: 207-12
110. Maes M, Libbrecht I, van Hunsel F, et al. Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance. J Clin Psychopharmacol 1999; 19: 177-82
111. Bymaster FP, Zhang W, Carter PA, et al. Fluoxetine, but not other selective serotonin re-uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Psychopharmacology 2002; 160: 353-61
112. Corya S, Dube S, Andersen SW, et al. Metanalysis of olanzepine-fluoxetine use in treatment resistant depression. CINP 2002a, P2E 042 Montreal
113. Corya S, Dube S, Andersen SW, et al. Olanzepine-Fluoxetine combination for psychotic major depression. CINP 2002c, P3E 026 Montreal
114. Corya S, Andersen SW, Dube S, et al. Long-term olanzepine-fluoxetine use in major depressive disorder; interim data CINP 2002b; P2E 041 Montreal
115. Corya S, Dube S, Andersen SW, et al. Safety metanalysis of olanzepine-fluoxetine combination versus placebo. CINP 2002d, P3E 028 Montreal
116. Zhang W, Perry KW, Wong DT, et al. Synergistic effects of olanzepine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology 2002; 23: 250-62
117. Hirose S, Ashby CR. An open pilot study combining risperidon and a selective serotonin reuptake inhibitor as initial antidepressant therapy. J Clin Psychiatry 2002; 63: 733-6
118. Janowsky DS, Overstreet DH. Cholinergic dysfunction in depression. Pharmacol Toxicol 1990; 66: 100-11
119. Risch SC, Kalin NH, Janowsky DS. Cholinergic challenges in affective illness: behavioral and neuroendocrine correlates. J Clin Psychopharmacol 1981; 1: 186-92
120. Kendler KS, Neale MC, MacLean CJ, et al. Smoking and major depression: a causal analysis. Arch Gen Psychiatry 1993; 50: 36-43
121. Glassman AH, Helzer JE, Covey LS, et al. Smoking, smoking cessation, and major depression. JAMA 1990; 264: 1546-9
122. Lerman C, Caporaso N, Main D, et al. Depression and self-medication with nicotine: the modifying influence of the dopamine D4 receptor gene. Health Psychol 1998; 17: 56-62
123. Tizabi Y, Overstreet DH, Rezvani AH, et al. Antidepressant effects of nicotine in an animal model of depression. Psychopharmacology 1999; 142: 193-9
124. Ferguson SM, Brodkin JD, Lloyd GK, et al. Antidepressant-like effects of the subtype-selective nicotinic acetylcholine receptor agonist, SIB-1508Y, in the learned helplessness rat model of depression. Psychopharmacology 2000; 152: 295-303
125. Williams M, Risley EA, Huff JR. Interaction of putative anxiolytic agents with central adenosine receptors. Can J Physiol Pharmacol 1981; 59: 897-900
126. El Yacoubi M, Ledent C, Parmentier M. Adenosine A2A receptor antagonists are potential antidepressants: evidence based on pharmacology and A2A receptor knockout mice. Br J Pharmacol 2001; 134: 68-77
127. Lloyd KG, Morselli PL, Bartholini G. GABA and affective disorders. Med Biol 1987; 65: 159-65
128. Riezen van H, Leonard BE. Effects of psychotropic drugs on the behavior and neurochemistry of olfactory bulbectomized rats. Pharmacol Ther 1990; 47: 21-34
129. Sanacora G, Mason GF, Rothman DL. Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors. Am J Psychiatry 2002; 159: 663-5
130. Taylor CB, Hayward C, King R, et al. Cardiovascular and symptomatic reduction effects of alprazolam and imipramine in patients with panic disorder: results of a double-blind, placebo-controlled trial. J Clin Psychopharmacol 1990; 10: 112-8
131. Feighner JP, Boyer WF, Hendrickson GG, et al. A controlled trial of adinazolam versus desipramine in geriatric depression. Int Clin Psychopharmacol 1990; 5: 227-32
132. Ansseau M, Devoitille JM, Papart P, et al. Comparison of adinazolam, amitriptyline, and diazepam in endogenous depressive inpatients exhibiting DST nonsuppression or abnormal contingent negative variations. J Clin Psychopharmacol 1991; 11: 160-5
133. Kennedy SH, De Groot J, Ralevski E, et al. A comparison of adinazolam and desipramine in the treatment of major depression. Int Clin Psychopharmacol 1991; 6: 65-76
134. Nowak G, Trullas R, Layer RT, et al. Adaptive changes in the N-methyl-D-aspartate receptor complex after chronic treatment with imipramine and 1-aminocyclopropanecarboxylic acid. J Pharmacol Exp Ther 1993; 265: 1380-6
135. Nowak G, Redmond A, McNamara M, et al. Swim stress increases the potency of glycine at the N-methyl-D-aspartate receptor complex. J Neurochem 1995; 64: 925-7
136. Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000; 47: 351-4
137. Robichaud M, Beauchemin V, Lavoie N. Effects of bilateral olfactory bulbectomy on N-methyl-D-aspartate receptor function: autoradiographic and behavioral studies in the rat. Synapse 2001; 42: 95-103
138. Spooren WP, Vassout A, Neijt HC, et al. Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6- (phenylethynyl)pyridine in rodents. J Pharmacol Exp Ther 2000; 295: 1267-75
139. Paul IA, Skolnick P. Glutamate and depression: clinical and preclinical studies. Ann N Y Acad Sci 2003; 1003: 250-72
140. Perez-Garcia C, Morales L, Cano MV. Effects of histamine H3 receptor ligands in experimental models of anxiety and depression. Psychopharmacology 1999; 142: 215-20
141. Lamberti C, Ipponi A, Bartolini A, et al. Antidepressant-like effects of endogenous histamine and of two histamine H1 receptor agonists in the mouse forced swim test. Br J Pharmacol 1998; 123: 1331-6
142. Arrang JM, Devaux B, Chodkiewicz JP, et al. H3-receptors control histamine release in human brain. J Neurochem 1998; 51: 105-8
143. Leurs R, Blandina P, Tedford C, et al. Therapeutic potential of histamine H3 receptor agonists and antagonists. Trends Pharmacol Sci 1998; 19: 177-83
144. Brunswick DJ, Hundert M, Amsterdam JD. A single-site, double-blind, placebo-controlled, dose-ranging study of YKP 10A: a putative, new antidepressant. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 1333-8
145. Weber MM, Emrich HM. Current and historical concepts of opiate treatment in psychiatric disorders. Int Clin Psychopharmacol 1988; 3: 255-66
146. Brooner RK, King VL, Kidorf M, et al. Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. Arch Gen Psychiatry 1997; 54: 71-80
147. Khawaja AM, Rogers DF. Tachykinins: receptor to effector. Int J Biochem Cell Biol 1996; 28: 721-38
148. Cutler NR, Kramer MS, Reines SA, et al. Single site results from a multicenter study of efficacy and safety of MK-869, an NK-1 antagonist, in patients with major depressive disorder [abstract]. Int J Neuropsychopharmacol 2000; 3 Suppl. 1: 7
149. Rupniak NMJ, Kramer MS. Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonists. Trends Pharmacol Sci 1999; 20: 485-90
150. Bondy B, Baghai TC, Minov C, et al. Substance P serum levels are increased in major depression: preliminary results. Biol Psychiatry 2003; 53: 538-42
151. Burnet PW, Harrison PJ. Substance P (NK1) receptors in the cingulate cortex in unipolar and bipolar mood disorder and schizophrenia. Biol Psychiatry 2000; 47: 80-3
152. Stockmeier CA, Shi X, Konick L, et al. Neurokinin-1 receptors are decreased in major depressive disorder. Neuroreport 2002; 13: 1223-7
153. van der Hart MGC, Czeh B, de Biurrun G, et al. Substance P receptor antagonist and clomipramine prevent stress-induced alterations in cerebral metabolites, cytogenesis in the dentate gyrus and hippocampal volume. Mol Psychiatry 2002; 7: 933-41
154. Blier P, Gobbi G, Haddjeri N, et al. Impact of substance P receptor antagonism on the serotonin and norepinephrine systems: relevance to the antidepressant/anxiolytic response. J Psychiatry Neurosci 2004; 29: 208-18
155. Valentino RJ, Bey V, Pernar L, et al. Substance P acts through local circuits within the rat dorsal raphe nucleus to alter serotonergic neuronal activity. J Neurosci 2003; 23: 7155-9
156. Guiard BP, Przbylski C, Guilloux J-P, et al. Blockade of substance P (neurokinin 1) receptors enhances extracellular serotonin when combined with a selective serotonin reuptake inhibitor: an in vivo microdialysis study in mice. J Neurochem 2004; 89: 54-63
157. Haddjeri N, Blier P. Sustained blockade of neurokinin-1 receptors enhances serotonin neurotransmission. Biol Psychiatry 2001; 50: 191-9
158. Snider RM, Constantine JW, Lowe III JA, et al. A potent non-peptide antagonist of the substance P (NK1) receptor. Science 1991; 251: 435-7
159. Papp M, Vassout A, Gentsch C. The NK1-receptor antagonist NKP608 has an antidepressant-like effect in the chronic mild stress model of depression in rats. Behav Brain Res 2000; 115: 19-23
160. Matsuno K, Kobayashi T, Tanaka MK, et al. Sigma 1 receptor subtype is involved in the relief of behavioral despair in the mouse forced swimming test. Eur J Pharmacol 1996; 312: 267-71
161. Pande AC, Geneve J, Scherrer B. Igmesine, a novel sigma ligand, has antidepressant properties [abstract]. Int J Neuropsychopharmcol 1998; 1 Suppl. 1: 8
162. Akunne HC, Zoski KT, Whetzel SZ, et al. Neuropharmacological profile of a selective sigma ligand, igmesine: a potential antidepressant. Neuropharmacology 2001; 41: 138-49
163. Tottori K, Miwa T, Uwahodo Y, et al. Antidepressant-like responses to the combined sigma and 5-HT1A receptor agonist OPC-14523. Neuropharmacology 2001; 41: 976-88
164. Steinberg R, Alonso R, Griebel G, et al. Selective blockade of neurokinin-2 receptors produces antidepressant-like effects associated with reduced corticotropin-releasing factor function. J Pharmacol Exp Ther 2001; 299: 449-58
165. Gold PW, Calabrese JR, Kling MA, et al. Abnormal ACTH and cortisol responses to ovine corticotrophin releasing factor in patients with primary affective disorder. Progress Neuropsychopharmacol Biol Psychiatry 1986; 10: 57-65
166. Gold PW, Kling MA, Khan I, et al. Corticotrophin releasing hormone: relevance to normal physiology and to the pathophysiology and differential diagnosis of hypercortisolism and adrenal insufficiency. Adv Biochem Psychopharmacol 1987; 43: 183-200
167. Maes M, Maes L, Suy E. Symptom profiles of biological markers in depression: a multivariate study. Psychoneuroendocrinology 1990; 15: 29-37
168. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 2000; 23: 477-501
169. Maes M, Minner B, Suy E. Cortisol escape from suppression by dexamethasone during depression is stronger predicted by basal hypersecretion and increasing age. Psychoneuroendocrinology 1991; 16: 295-310
170. Van Cauter E, LeProult R, Kupfer DJ. Effects of gender and age on the levels and circadian rhythmicity of plasma cortisol. J Clin Endocrinol Metab 1996; 81: 2468-73
171. Nestler EJ. Antidepressant treatments in the 21st century. Biol Psychiatry 1998; 44: 526-33
172. Wolkowitz OM, Reus VI. Treatment of depression with antiglucocorticoid drugs. Pyschosom Med 1999; 61: 698-711
173. Wolkowitz OM, Reus VI, Keebler A, et al. Double-blind treatment of major depression with dehydroepiandrosterone. Am J Psychiatry 1999; 156: 646-9
174. Keppel-Hesselink JM. Prasterone (dihydroepiandrosterone): a modern source of eternal youth? Ned Tijdschr Geneeskd 1997; 141: 2484-7
175. Dean CE. Prasterone (DHEA) and mania. Ann Pharmacother 2000; 34: 1419-22
176. Zobel AW, Nickel T, Kunzel HEM, et al. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res 2000; 34: 171-81
177. Belanoff JK, Flores BH, Kalezhan M. Rapid reversal of psychotic depression using mifepristone. J Clin Psychopharmacol 2001; 21: 516-21
178. Belanoff J, Rothschild A, Cassidy F, et al. An open label trial of C-1073 (mifepristone) for psychotic major depression. Biol Psychiatry 2002; 52: 386-92
179. Hoyberg J, Wik G, Mehtonen OP, et al. ORG 34517, a selective glucocorticoid receptor antagonist with potent antidepressant activity: first clinical results [abstract]. Int J Neuropsychopharmacol 2002; 5 Suppl. 1: 148
180. Healy DG, Harkin A, Cryan JF, et al. Metyrapone displays antidepressant-like properties in preclinical paradigms. Psychopharmacology 1999; 145: 303-8
181. Murphy BE, Ghadirian AM, Dhar V. Neuroendocrine responses to inhibitors of steroid biosynthesis in patients with major depression resistant to antidepressant therapy. Can J Psychiatry 1998; 43: 279-86
182. Feighner JP, Ehrensing RH, Kastin AJ, et al. Double-blind, placebo-controlled study of INN 00835 (netamiftide) in the treatment of outpatients with major depression. Int Clin Psychopharmacol 2001; 16: 345-52
183. Ying SW, Rusak B, Delagrange P, et al. Melatonin analogues as agonists and antagonists in the circadian system and other brain areas. Eur J Pharmacol 1996; 296: 33-42
184. Loo H, Hale A, D'haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol 2002; 17: 239-47
185. Biagini G, Pich EM, Carani C, et al. Indole-pyruvic acid, a tryptophan ketoanalogue, antagonizes the endocrine but not the behavioral effects of repeated stress in a model of depression. Biol Psychiatry 1993; 33: 712-9
186. Hatzinger M. Neuropeptides and the hypothalamic-pituitary-adrenocortical (HPA) system: review of recent research strategies in depression. World J Biol Psychiatry 2000; 1: 105-11
187. Parker KJ, Schatzberg AF, Lyons DM. Neuroendocrine aspects of hypercortisolism in major depression. Horm Behav 2003; 43: 60-6
188. Murphy BE. Antiglucocorticoid therapies in major depression: a review. Psychoneuroendocrinology 1997; 22 Suppl. 1: S125-32
189. McQuade R, Young AH. Future therapeutic targets in mood disorders: the glucocorticoid receptor. Br J Psychiatry 2000; 177: 390-5
190. Florijn WJ, Mulder AH, Versteeg DH, et al. Adrenocorticotropin/alpha- melanocyte-stimulating hormone (ACTH/MSH)-like peptides modulate adenylate cyclase activity in rat brain slices: evidence for an ACTH/MSH receptor-coupled mechanism. J Neurochem 1993; 60: 2204-11
191. Tonon MC, Leroux P, Stoeckel ME, et al. Catecholaminergic control of alpha-melanocyte-stimulating hormone (alpha MSH) release by frog neurointermediate lobe in vitro: evidence for direct stimulation of alpha-MSH release by thyrotropin-releasing hormone. Endocrinology 1983; 112: 133-41
192. Pignatiello MF, Olson GA, Kastin AJ. MIF-1 is active in a chronic stress animal model of depression. Pharmacol Biochem Behav 1989; 32: 737-42
193. Kostowski W, Danysz W, Dyr W, et al. MIF-1 potentiates the action of tricyclic antidepressants in an animal model of depression. Peptides 1991; 12: 915-8
194. Ehrensing RH, Kastin AJ, Wurzlow GF, et al. Improvement in major depression after low subcutaneous doses of MIF-1. J Affect Disord 1994; 31: 227-33
195. Halbreich U, Kahn LS. Role of estrogen in the aetiology and treatment of mood disorders. CNS Drugs 2001; 15: 797-817
196. Joffe H, Cohen LS. Estrogen, serotonin, and mood disturbance: where is the therapeutic bridge? Biol Psychiatry 1998; 44: 798-811
197. Rubinow DR, Schmidt PJ, Roca CA. Estrogen-serotonin interactions: implications for affective regulation. Biol Psychiatry 1998; 44: 839-50
198. Osterlund MK, Halldin C, Hurd YL. Effects of chronic 17beta-estradiol treatment on the serotonin 5-HT(1A) receptor mRNA and binding levels in the rat brain. Synapse 2000; 35: 39-44
199. Raap DK, DonCarlos L, Garcia F. Estrogen desensitizes 5-HT(1A) receptors and reduces levels of G(Z), G(i1) and G(i3) proteins in the hypothalamus. Neuropharmacology 2000; 39: 1823-32
200. Birzniece V, Johansson IM, Wang MD, et al. Ovarian hormone effects on 5-hydroxytryptamine(2A) and 5-hydroxy-tryptamine(2C) receptor mRNA expression in the ventral hippocampus and frontal cortex of female rats. Neurosci Lett 2002; 319: 157-61
201. George MS, Ketter TA, Parekh PI, et al. Gender differences in regional cerebral blood flow during transient self-induced sadness or happiness. Biol Psychiatry 1996; 40: 859-71
202. Handa RJ, Burgess LH, Kerr JE, et al. Gonadal steroid hormone receptors and sex differences in the hypothalamo-pituitary-adrenal axis. Horm Behav 1994; 28: 464-76
203. Carey MP, Deterd CH, de Koning J, et al. The influence of ovarian steroids on hypothalamic-pituitary-adrenal regulation in the female rat. J Endocrinol 1995; 144: 311-21
204. DeLeo V, la Marca A, Talluri B, et al. Hypothalamo-pituitary-adrenal axis and adrenal function before and after ovariectomy in premenopausal women. Eur J Endocrinol 1998; 138: 430-5
205. Shupnik MA. Oestrogen receptors, receptor variants and oestrogen actions in the hypothalamic-pituitary axis. J Neuroendocrinol 2002; 14: 85-94
206. Shughrue PJ, Merchenthaler I. Distribution of estrogen receptor beta immunoreactivity in the rat central nervous system. J Comp Neurology 2001; 436: 64-81
207. McEwen BS. Invited review: estrogens effects on the brain: multiple sites and molecular mechanisms. J Appl Physiol 2001; 91: 2785-801
208. Gruber CJ, Tschugguel W, Schneeberger C, et al. Production and actions of estrogens. N Engl J Med 2002; 346: 340-52
209. Carranza-Lira S, Valentino-Figueroa ML. Estrogen therapy for depression in postmenopausal women. Int J Gynaecol Obstet 1999; 65: 35-8
210. Soares CN, Almeida OP, Joffe H, et al. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry 2001; 58: 529-34
211. Friebely JS, Shifren JL, Schiff I, et al. Preliminary observations on differing psychological effects of conjugated and esterified estrogen treatments. J Womens Health Gend Based Med 2001; 10: 181-7
212. Davis SR. The effects of tibolone on mood and libido. Menopause 2002; 9: 162-70
213. Khoo SK, Coglan M, Battistutta D, et al. Hormonal treatment and psychological function during the menopausal transition: an evaluation of the effects of conjugated estrogens/cyclic medroxyprogesterone acetate. Climacteric 1998; 1: 55-62
214. Paoletti AM, Floris S, Mannias M. Evidence that cyproterone acetate improves psychological symptoms and enhances the activity of the dopaminergic system in postmenopause. J Clin Endocrinol Metab 2001; 86: 608-12
215. Rasgon NL, Altshuler LL, Fairbanks LA. Estrogen replacement therapy in the treatment of major depressive disorder in perimenopausal women. J Clin Psychiatry 2002; 63 Suppl. 7: 45-8
216. Strickler R, Stovall DW, Merritt D, et al. Raloxifene and estrogen effects on quality of life in healthy postmenopausal women: a placebo-controlled randomized trial. Obstet Gynecol 2000; 96: 359-65
217. Ruggiero RJ, Likis FE. Estrogen: physiology, pharmacology, and formulations for replacement therapy. J Midwifery Womens Health 2002; 47: 130-8
218. Diel P. Tissue-specific estrogenic response and molecular mechanisms. Toxicol. Lett 2002; 127: 217-24
219. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33
220. Anderson GL, Limacher M, Curb D, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291: 1701-12
221. Liske E, Hanggi W, Henneicke von Zepelin HH, et al. Physiological investigation of a unique extract of black cohosh (Cimicifugae racemosae rhizoma): a 6-month clinical study demonstrates no systemic estrogenic effect. J Womens Health Gend Based Med 2002; 11: 163-74
222. McDonnell DP. The Molecular Pharmacology of SERMs. Trends Endocrinol Metab 1999; 10: 301-11
223. Sandberg K. HRT and SERMs: the good, the bad em leader and the lovely? Trends Endocrinol Metab 2002; 13: 317-8
224. Bourin M, Mocaer E, Porsolt R. Antidepressant-like activity of S20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors. J Psychiatry Neurosci 2004; 29: 126-33
225. Vaidya VA, Duman RS. Depresssion-emerging insights from neurobiology. Br Med Bull 2001; 57: 61-79
226. Nestler EJ, Barrot M, DiLeone RJ, et al. Neurobiology of depression. Neuron 2002; 34: 13-25
227. Nibuya M, Nestler EJ, Duman RS. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J Neurosci 1996; 16: 2365-72
228. Dowlatshahi D, MacQueen GM, Wang JF, et al. Increased temporal cortex CREB concentrations and antidepressant treatment in major depression. Lancet 1998; 352: 1754-5
229. Thome J, Sakai N, Shin K, et al. cAMP response element-mediated gene transcription is upregulated by chronic antidepressant treatment. J Neurosci 2000; 20: 4030-6
230. Chen AC, Shirayama Y, Shin KH, et al. Expression of the cAMP response element binding protein (CREB) in hippocampus produces an antidepressant effect. Biol Psychiatry 2001; 49: 753-62
231. Conti AC, Cryan JF, Dalvi A, et al. cAMP response element-binding protein is essential for the upregulation of brain-derived neurotrophic factor transcription, but not the behavioral or endocrine responses to antidepressant drugs. J Neurosci 2002; 22: 3262-8
232. Trentani A, Kuipers SD, Ter Horst GJ, et al. Selective chronic stress-induced in vivo ERK1/2 hyperphosphorylation in medial prefrontocortical dendrites: implications for stress-related cortical pathology? Eur J Neurosci 2002; 15: 1681-91
233. Lim J, Yang C, Hong SJ, et al. Regulation of tyrosine hydroxylase gene transcription by the cAMP-signaling pathway: involvement of multiple transcription factors. Mol Cell Biochem 2000; 212: 51-60
234. Smith MA, Makino S, Kvetnansky R, et al. Effects of stress on neurotrophic factor expression in the rat brain. Ann N Y Acad Sci 1995; 771: 234-9
235. Rasmusson AM, Shi L, Duman R. Downregulation of BDNF mRNA in the hippocampal dentate gyrus after re-exposure to cues previously associated with footshock. Neuropsychopharmacology 2002; 27: 133-42
236. Karege F, Perret G, Bondolfi G, et al. Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res 2002; 109: 143-8
237. Altar CA. Neurotrophins and depression. Trends Pharmacol Sci 1999; 20: 59-61
238. Chen B, Dowlatshahi D, MacQueen GM, et al. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry 2001; 50: 260-5
239. Mori S, Zanardi R, Popoli M, et al. cAMP-dependent phosphorylation system after short and long-term administration of moclobemide. J Psychiatr Res 1998; 32: 111-5
240. Shelton RC, Manier DH, Peterson CS. Cyclic AMP-dependent protein kinase in subtypes of major depression and normal volunteers. Int J Neuropsychopharmacol 1999; 2: 187-92
241. Perez J, Tardito D, Racagni G. cAMP signaling pathway in depressed patients with psychotic features. Mol Psychiatry 2002; 7: 208-12
242. Hetman M, Kanning K, Cavanaugh JE, et al. Neuroprotection by brain-derived neurotrophic factor is mediated by extracellular signal-regulated kinase and phosphatidylinositol 3-kinase. J Biol Chem 1999; 274: 22569-80
243. Manji HK, Moore GJ, Rajkowska G, et al. Neuroplasticity and cellular resilience in mood disorders. Mol Psychiatry 2000; 5: 578-93
244. Mai L, Jope RS, Li X. BDNF-mediated signal transduction is modulated by GSK3beta and mood stabilizing agents. J Neurochem 2002; 82: 75-83
245. Dwivedi Y, Rizavi HS, Roberts RC, et al. Reduced activation and expression of ERK1/2 MAP kinase in the post-mortem brain of depressed suicide subjects. J Neurochem 2001; 77: 916-28
246. Pompe van der G, Schneiderman N. Psychoneuroimmunology. In: Kaptein AA, Appels A, Orth-Gomer K, editors. Psychology in medicine. Houten: Bohn Stafleu van Loghum, 2000
247. van West D, Maes M. Activation of the inflammatory response system: a new look at the etiopathogenesis of major depression. Neuroendocrinol Lett 1999; 20: 11-7
248. Capuron L, Dantzer R. Cytokines and depression: the need for a new paradigm. Brain Behav Immun 2003; 17 Suppl. 1: S119-24
249. Leonard BE. Changes in the immune system in depression and dementia: causal or co-incidental effects? Int J Dev Neurosci 2001; 19: 305-12
250. Bonaccorso S, Marino V, Puzella A, et al. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J Clin Psychopharmacol 2002; 22: 86-90
251. Lichtenstein GR, Bala M, Han C, et al. Infliximab improves quality of life in patients with Crohn's disease. Inflamm Bowel Dis 2002; 8: 237-43
252. Liotti M, Mayburg HS, McGinns S, et al. Unmasking disease-specific cerebral blood flow abnormalities: mood challenge in patients with remitted unipolar depression. Am J Psychiatry 2002; 159: 1830-40
253. Mayberg HS, Silva J, Branan SK, et al. The functional neuroanatomy of the placebo effect. Am J Psychiatry 2002; 159: 728-37
254. Korf J, Klein H, Versijpt J, et al. Considering depression as a consequence of activation of the inflammatory response system. Acta Neuropsychiat 2002; 14: 1-10
255. Ribeiro SCM, Tandom R, Grunhaus L. The DST as a predictor of outcome in depression: a meta-analysis. Am J Psychiatry 1993; 150: 1618-29
256. Korf J. Cortisol bij depressies: te hoog, te laag of niet op tijd? [Cortisol in depression: too high, too low or not in time?]. Tijdschrift voor Psychiatrie 2002; 44: 323-32
257. De Kloet ER, Oitzl MS, Joels M. Stress and cognition: are corticoids good or bad guys? Trends Neurosci 1999; 22: 422-6
258. Russo S, Kema IP, Fokkema MR, et al. Tryptophan as a link between psychopathology and somatic states. Psychosom Med 2003; 65: 665-71
259. Neumeister A, Konstatinides A, Stastny J, et al. Association between serotonin transporter gene promoter polymorphism (5HTTLPR) and behavioral responses to tryptophan depletion in healthy women with and without family history of depression. Arch Gen Psychiatry 2002; 59: 613-20
260. Van Praag HM, Kahn RS, Asnis GM, et al. Denosologization of biological psychiatry or the specificity of 5-HT disturbances in psychiatric disorders. J Affect Disord 1987; 13: 1-8
261. Weissman MM, Bland RC, Canino GJ, et al. Cross-national epidemiology of major depression and bipolar disorder. JAMA 1996; 276: 293-9
262. Spijker J, Bijl RV, Nolen WA. Duur van depressieve episoden en determinanten van beloop. Tijdschrift voor Psychiatrie 2004; 46 (4): 229-35
263. Spijker J, Bijl RV, De Graaf R. Care utilization and outcome of DSM III-R major depression in the general population. Results from the Netherlands Mental Health Survey and Incidence Study (NEMESIS). Acta Psychiatr Scand 2001; 104: 19-24
264. Nesse RM. Is depression an adaptation? Arch Gen Psychiatry 2000; 57: 390-5